Selected Publications
Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12
Troester S, Eder T, Wukowits N, Piontek M, Fernández-Pernas P, Schmoellerl J, Haladik B, Manhart G, Allram M, Maurer-Granofszky M, Scheidegger N, Nebral K, Superti-Furga G, Meisel R, Bornhauser B, Valent P, N. Dworzak M, Zuber J, Boztug K & Grebien F
Nature Communications; May 2025. Available at https://www.nature.com/articles/s41467-025-59930-9
RNA sequestration in P-bodies sustains myeloid leukaemia
Kodali S, Proietti L, Valcarcel G, López-Rubio AV, Pessina P, Eder T, Shi J, Jen A, Lupión-Garcia N, Starner AC, Bartels MD, Cui Y, Sands CM, Planas-Riverola A, Martínez A, Velasco-Hernandez T, Tomás-Daza L, Alber B, Manhart G, Mayer IM, Kollmann K, Fatica A, Menendez P, Shishkova E, Rau RE, Javierre BM, Coon J, Chen Q, Van Nostrand EL, Sardina JL, Grebien F, Di Stefano B.
Nature Cell Biology; August 2024. Available at https://www.nature.com/articles/s41556-024-01489-6
2025
Harnessing the E3 ligase SPOP for targeted degradation of the NUP98::KDM5A fusion oncoprotein.
Kirkiz E, Kaufmann G, Bergqvist S, Fernández-Pernas P, Eder T, Quell L, Allram M, Manhart G, Walter W, Haferlach T, Grebien F.
Cell Rep. 2025 Dec. Available at https://www.cell.com/cell-reports/fulltext/S2211-1247(25)01374-9
Probing condensate microenvironments with a micropeptide killswitch.
Zhang Y, Stöppelkamp I,Fernandez-Pernas P, Allram M, Charman M, Magalhaes AP, Piedavent-Salomon M, Sommer G, Sung YC, Meyer K, Grams N, Halko E, Dongre S, Meierhofer D, Malszycki M, Ilik IA, Aktas T, Kraushar ML, Vastenhouw N, Weitzman MD, Grebien F, Niskanen H, Hnisz D.
Nature. 2025 Jul. Available at https://www.nature.com/articles/s41586-025-09141-5
Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12.
Troester S, Eder T, Wukowits N, Piontek M, Fernández-Pernas P, Schmoellerl J, Haladik B, Manhart G, Allram M, Maurer-Granofszky M, Scheidegger N, Nebral K, Superti-Furga G, Meisel R, Bornhauser B, Valent P, N. Dworzak M, Zuber J, Boztug K & Grebien F.
Nat Comm.; May 2025. available at https://www.nature.com/articles/s41467-025-59930-9
DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes.
Kaya F, Bewicke-Copley F, Miettinen JJ, Casado P, Leddy E, Deniz Ö, Lavallée VP, Philippe C, Zheng J, Grebien F, Khan N, Krizsán S, Saad J, Nolin-Lapalme A, Hébert J, Lemieux S, Audemard E, Matthews J, Grantham M, Di Bella D, Wennerberg K, Parsons A, Gribben J, Cavenagh JD, Freeman SD, Bödör C, Sauvageau G, Wang J, Llamas-Sillero P, Cazier JB, Taussig DC, Bonnet D, Cutillas PR, Heckman CA, Fitzgibbon J, Rouault-Pierre K, Rio-Machin A.
Leukemia. 2025 June; available at https://www.nature.com/articles/s41375-025-02593-8
Clec12a is required for the pathogenesis of NUP98::NSD1 AML.
Mohanty S, Charles Cano F, Gabdoulline R, Lai CK, Othman B, Sudarsanam H, Eder T, Grebien F, Lipka DB, Henschler R, Heuser M.
Blood Adv. 2025 May Available at https://doi.org/10.1182/bloodadvances.2024015739
Deciphering the code of resistance: a genomic and transcriptomic exploration of the Cystoisospora suis Holland-I strain.
Cruz-Bustos T, Eder T, Ruttkowski B, Joachim A.
Sci Rep.; February 2025. available at https://doi.org/10.1038/s41598-025-89372-8
2024
Off-Target Inhibition of Human Dihydroorotate Dehydrogenase (hDHODH) Highlights Challenges in the Development of Fat Mass and Obesity-Associated Protein (FTO) Inhibitors.Tarullo M, Fernandez Rodriguez G, Iaiza A, Venezia S, Macone A, Incocciati A, Masciarelli S, Marchioni M, Giorgis M, Lolli ML, Fornaseri F, Proietti L, Grebien F, Rosignoli S, Paiardini A, Rotili D, Mai A, Bochenkova E, Caflisch A, Fazi F, Fatica A.ACS Pharmacol Transl Sci. 2024 November, available at https://pubs.acs.org/doi/10.1021/acsptsci.4c00533
Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma.
Pölöske D, Sorger H, Schönbichler A, de Araujo ED, Neubauer HA, Orlova A, Timonen SH, Abdallah DI, Ianevski A, Kuusanmäki H, Surbek M, Heyes E, Eder T, Wagner C, Suske T, Metzelder ML, Bergmann M, Dahlhoff M, Grebien F, Fleck R, Pirker C, Berger W, Hadzijusufovic E, Sperr WR, Kenner L, Valent P, Aittokallio T, Herling M, Mustjoki S, Gunning PT, Moriggl R.
Hemasphere; November 2024. available at https://onlinelibrary.wiley.com/doi/10.1002/hem3.70001
The adsorption of drugs on nanoplastics has severe biological impact.
Dick L, Batista PR, Zaby P, Manhart G, Kopatz V, Kogler L, Pichler V, Grebien F, Bakos V, Plósz BG, Kolev NZ, Kenner L, Kirchner B, Hollóczki O.
Sci Rep. 2024 October, available at https://www.nature.com/articles/s41598-024-75785-4
NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities.
Rasouli M, Troester S, Grebien F, Goemans BF, Zwaan CM, Heidenreich O.
Hemasphere; September 2024. available at https://onlinelibrary.wiley.com/doi/10.1002/hem3.70013
RNA sequestration in P-bodies sustains myeloid leukaemia.
Kodali S, Proietti L, Valcarcel G, López-Rubio AV, Pessina P, Eder T, Shi J, Jen A, Lupión-Garcia N, Starner AC, Bartels MD, Cui Y, Sands CM, Planas-Riverola A, Martínez A, Velasco-Hernandez T, Tomás-Daza L, Alber B, Manhart G, Mayer IM, Kollmann K, Fatica A, Menendez P, Shishkova E, Rau RE, Javierre BM, Coon J, Chen Q, Van Nostrand EL, Sardina JL, Grebien F, Di Stefano B.
Nature cell biology; August 2024. available at https://www.nature.com/articles/s41556-024-01489-6
Differential regulation of mitochondrial uncoupling protein 2 in cancer cells.
Beikbaghban T, Proietti L, Ebner J, Sango R, Rattei T, Weichhart T, Grebien F, Sternberg F, Pohl EE.
Biochim Biophys Acta Bioenerg. 2024 November, available at https://doi.org/10.1016/j.bbabio.2024.149486
A novel function of STAT3β in suppressing interferon response improves outcome in acute myeloid leukemia.
Edtmayer S, Witalisz-Siepracka A, Zdársky B, Heindl K, Weiss S, Eder T, Dutta S, Graichen U, Klee S, Sharif O, Wieser R, Győrffy B, Poli V, Casanova E, Sill H, Grebien F, Stoiber.
Cell death & disease; May 2024. available at https://www.nature.com/articles/s41419-024-06749-9
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.
Suske T, Sorger H, Manhart G, Ruge F, Prutsch N, Zimmermann MW, Eder T, Abdallah DI, Maurer B, Wagner C, Schönefeldt S, Spirk K, Pichler A, Pemovska T, Schweicker C, Pölöske D, Hubanic E, Jungherz D, Müller TA, Aung MMK, Orlova A, Pham HTT, Zimmel K, Krausgruber T, Bock C, Müller M, Dahlhoff M, Boersma A, Rülicke T, Fleck R, de Araujo ED, Gunning PT, Aittokallio T, Mustjoki S, Sanda T, Hartmann S, Grebien F, Hoermann G, Haferlach T, Staber PB, Neubauer H, Look AT, Herling M, Moriggl R.
J Clin Investigation; April 2024. available at https://doi.org/10.1172/JCI168536
2023
TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.
Heyes E, Wilhemson AS, Wenzel A, Manhart G, Eder T, Schuster MB, Rzepa E, Pundhir S, D’altri T, Frank A, Gentil C, Woessmann J, Schoof EM, Meggendorfer M, Schwaller J, Haferlach T, Grebien F, Porse BT.
Nat Commun.; October 2023. available at https://doi.org/10.1038/s41467-023-41927-x
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia.
Ebner J, Schmoellerl J, Piontek M, Manhart G, Troester S, Carter B, Neubauer H, Moriggl R, Szakács G, Zuber J, Köcher T, Andreeff M, Sperr W, Valent P, Grebien F.
Nat Commun.; September 2023. available at https://doi.org/10.1038/s41467-023-41229-2
The Intricacies of Inflammatory Bowel Disease: A Preliminary Study of Redox Biology in Intestinal Organoids.
Csukovich G, Huainig J, Troester S, Pratscher B, Burgener IA.
Organoids; September 2023. available at https://doi.org/10.3390/organoids2030012
The MLL–Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML.
Rasouli M, Blair H, Troester S, Szoltysek K, Cameron R, Ashtiani M, Krippner-Heidenreich A, Grebien F, McGeehan G, Zwaan CM, Heidenreich O.
Hemasphere; August 2023. available at https://doi.org/10.1097/HS9.0000000000000935
Histone Variants and Their Chaperones in Hematological Malignancies.
Kirkiz E, Meers O, Grebien F, Buschbeck M.
Hemasphere; July 2023. available at https://doi.org/10.1097/HS9.0000000000000927
Biomolecular Condensates in Myeloid Leukemia: What Do They Tell Us?
Jevtic Z, Allram M, Grebien F, Schwaller J.
Hemasphere; June 2023. available at https://doi.org/10.1097/HS9.0000000000000923
SBNO2 is a critical mediator of STAT3-driven hematological malignancies.
Brandstoetter T, Schmoellerl J, Grausenburger R, Kollmann S, Doma E, Huuhtanen J, Klampfl T, Eder T, Grebien F, Hoermann G, Zuber J, Mustjoki S, Maurer B, Sexl V.
Blood; April 2023. Online ahead of print. available at https://doi.org/10.1182/blood.2022018494
Antiviral immune response reveals host-specific virus infections in natural ant populations.
Viljakainen L, Fürst MA, Grasse AV, Jurvansuu J, Oh J, Tolonen L, Eder T, Rattei T, Cremer S.
Front Microbiol.; March 2023. available at https://doi.org/10.3389/fmicb.2023.1119002
EVI1 drives leukemogenesis through aberrant ERG activation.
Schmoellerl J, Barbosa IAM, Minnich M, Andersch F, Smeenk L, Havermans M, Eder T, Neumann T, Jude J, Fellner M, Ebert A, Steininger M, Delwel R, Grebien F, Zuber J.
Blood; February 2023. available at https://doi.org/10.1182/blood.2022016592
2022
Arrayed CRISPR/Cas9 Screening for the Functional Validation of Cancer Genetic Dependencies.
Proietti L, Manhart G, Heyes E, Troester S, Grebien F.
Bio Protoc.; December 2022. available at https://doi.org/10.21769/BioProtoc.4577
Decoding molecular programs in melanoma brain metastases.
Radke J, Schumann E, Onken J, Koll R, Acker G, Bodnar B, Senger C, Tierling S, Möbs M, Vajkoczy P, Vidal A, Högler S, Kodajova P, Westphal D, Meier F, Heppner F, Kreuzer-Redmer S, Grebien F, Jürchott K, Redmer T.
Nat Commun.; November 2022. available at https://doi.org/10.1038/s41467-022-34899-x
Identification of CD4+ T cells with T follicular helper cell characteristics in the pig.
Hoog A, Villanueva-Hernández S, Adib Razavi M, van Dongen K, Eder T, Piney L, Chapat L, de Luca K, Grebien F, Mair KH, Gerner W.
Dev. Comp Immunology; September 2022, available at https://doi.org/10.1016/j.dci.2022.104462
A Journey Into the Unknown: PhD Students in a European Training Network on Age-related Changes in Hematopoiesis Conduct Their Project During a Global Pandemic
Pitsillidou C, Alonso-Rubido S, Ávila-Ávila A, Romero-Mulero MC, Labedz A, Oikonomou A, Proietti L, Psychoyiou ME, Tellez-Quijorna C, Hillary M, Fasouli ES, Fernández-Rodríguez G, Giner-Laguarda N, Skinder N, Taroni C, Strouboulis J, Katsantoni E, Ronchi AE
Hemasphere; August 2022, available at https://doi.org/10.1097/HS9.0000000000000763
Increasing test specificity without impairing sensitivity: lessons learned from SARS-CoV-2 serology.
Perkmann T, Koller T, Perkmann-Nagele N, Ozsvar-Kozma M, Eyre D, Matthews P, Bown A, Stoesser N, Breyer MK, Breyer-Kohansal R, Burghuber OC, Hartl S, Aletaha D, Sieghart D, Quehenberger P, Marculescu R, Mucher P, Radakovics A, Klausberger M, Duerkop M, Holzer B, Hartmann B, Strassl R, Leitner G, Grebien F, Gerner W, Grabherr R, Wagner OF, Binder CJ, Haslacher H.
J Clin Pathol.; August 2022, available at https://doi.org/10.1136/jcp-2022-208171
Comprehensive assessment of differential ChIP-seq tools guides optimal algorithm selection.
Eder, T, Grebien, F.
Genome Biol.; May 2022, available at https://doi.org/10.1186/s13059-022-02686-y
Designed SARS-CoV-2 receptor binding domain variants form stable monomers.
Klausberger M, Kienzl NF, Stadlmayr G, Grünwald-Gruber C, Laurent E, Stadlbauer K, Stracke F, Vierlinger K, Hofner M, Manhart G, Gerner W, Grebien F, Weinhäusel A, Mach L, Wozniak-Knopp G.
Biotechnol J.; May 2022, available at https://doi.org/10.1002/biot.202100422
2021
Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness.
Grandits AM, Nguyen CH, Schlerka A, Hackl H, Sill H, Etzler J, Heyes E, Stoiber D, Grebien F, Heller G, Wieser R.
Leukemia; October 2021, available at https://www.nature.com/articles/s41375-021-01224-2.
Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter
van der Kouwe E, Heller G, Czibere A, Pulikkan JA, Agreiter C, Castilla LH, Delwel R, Di Ruscio A, Ebralidze AK, Forte M, Grebien F, Heyes E, Kazianka L, Klinger J, Kornauth C, Le T, Lind K, Inês Amorim Monteiro Barbosa, Pemovska T, Pichler AS, Schmolke AS, Schweicker CM, Sill H, Sperr WR, Spittler A, Surapally S, Trinh BQ, Valent P, Vanura K, Welner RS, Zuber J, Tenen DG, Staber PB
Blood; October 2021, available at https://doi.org/10.1182/blood.2020008971
Impact of Specific N-Glycan Modifications on the Use of Plant-Produced SARS-CoV-2 Antigens in Serological Assays.
Schwestka J, König-Beihammer J, Shin YJ, Vavra U, Kienzl NF, Grünwald-Gruber C, Maresch D, Klausberger M, Laurent E, Stadler M, Manhart G, Huber J, Hofner M, Vierlinger K, Weinhäusel A, Swoboda I, Binder CJ, Gerner W, Grebien F, Altmann F, Mach L, Stöger E, Strasser R.
Front Plant Sci.; September 2021, available at https://www.frontiersin.org/articles/10.3389/fpls.2021.747500/full.
Discovery of a Non-Nucleoside SETD2 Methyltransferase Inhibitor against Acute Myeloid Leukemia
Bajusz D†, Bognár Z†, Ebner J†, Grebien F, Keserű GM
Int. J. Mol. Sci.; September 2021, available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471172/.
Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML
Heyes E, Schmidt L, Manhart G, Eder T, Proietti L, Grebien F.
Leukemia; September 2021, available at https://www.nature.com/articles/s41375-021-01169-6
Exploring protein hotspots by optimized fragment pharmacophores
Bajusz D, Wade WS, Satała G, Bojarski AJ, Ilaš J, Ebner J, Grebien F, Papp H, Jakab F, Douangamath A, Fearon D, von Delft F, Schuller M, Ahel I, Wakefield A, Vajda S, Gerencsér J, Pallai P & Keserű GM
Nature Communications; May 2021, available at https://www.nature.com/articles/s41467-021-23443-y
Regulation of the Mitochondrion-Fatty Acid Axis for the Metabolic Reprogramming of Chlamydia trachomatis during Treatment with β-Lactam Antimicrobials
Shima K , Kaufhold I, Eder T , Käding N, Schmidt N, Ogunsulire IM, Deenen R, Köhrer K, Friedrich D, Isay SE, Grebien F, Klinger M, Richer BC, Günther UL, Deepe Jr GS , Rattei T, Rupp J.
mBio; March 2021, available at https://mbio.asm.org/content/12/2/e00023-21.long
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions
Valent P, Orfao A, Kubicek S, Staber P, Haferlach T, Deininger M, Kollmann K, Lion T, Virgolini I, Winter G, Hantschel O, Kenner L, Zuber J, Grebien F, Moriggl R, Hoermann G, Hermine O, Andreeff M, Bock C, Mughal T,Constantinescu SN, Kralovics R, Sexl V, Skoda R, Superti-Furga G,4 and Jäger U.
Hemasphere, February 2021, available at https://pubmed.ncbi.nlm.nih.gov/33623882/
Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression
Terlecki-Zaniewicz S, Humer T, Eder T, Schmoellerl J, Heyes E, Manhart G, Kuchynka N, Parapatics K, Liberante FG, Müller AC, Tomazou EM, Grebien F.
Nature Structural & Molecular Biology; January 2021, available at https://nature.com/articles/s41594-020-00550-w
2020
Mol Metab. 2020 Oct;40:101026. doi: 10.1016/j.molmet.2020.101026. available at https://pubmed.ncbi.nlm.nih.gov/32473405/
Cancers (Basel). 2020 Sep 26;12(10). doi: 10.3390/cancers12102766. available at https://pubmed.ncbi.nlm.nih.gov/32993115/
CDK6 is an essential direct target of NUP98-fusion proteins in acute myeloid leukemia
Schmoellerl J, Barbosa I, Eder T, Brandstoetter T, Schmidt L, Maurer B, Troester S, Pham HTT, Sagarajit M, Ebner J, Manhart G, Aslan E, Terlecki-Zaniewicz S, Van der Veen C, Hoermann G, Duployez N, Petit A, Lapillonne H, Puissant A, Itzykson RA, Moriggl RH, Heuser M, Meisel R, Valent P, Sexl V, Zuber J, Grebien F.
Blood; April 2020, pii: blood.2019003267, available at https://www.ncbi.nlm.nih.gov/pubmed/32344427
Gain‐of‐Function Effects of N‐Terminal CEBPA Mutations in Acute Myeloid Leukemia
Schmidt L, Heyes E, Grebien F.
BioEssays; January 2020, 1900178, available at https://pubmed.ncbi.nlm.nih.gov/31867767/
HBO1 is required for the maintenance of leukaemia stem cells
MacPherson L, Anokye J, Yeung MM, Lam EYN, Chan Y-C, Weng C-F, Yeh P, Knezevic K, Butler MS, Hoegl A, Chan K-L, Burr ML, Gearing LJ, Willson T, Liu J, Choi J, Yang Y, Bilardi RA, Falk H, Nguyen N, … , Grebien F, Dawson SJ, Street IP, Monahan BJ, Burns CJ, Choudhary , Blewitt ME, Voss AK, Thomas T & Dawson MA.
Nature; January 2020, 577: 266–270, available at https://pubmed.ncbi.nlm.nih.gov/31827282/
Haematologica. 2020;105(2):435-447, available at https://pubmed.ncbi.nlm.nih.gov/31123029/
2019
All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia
Nguyen CH, Bauer K, Hackl H, Schlerka A, Koller E, Hladik A, Stoiber D, Zuber J, Staber PB, Hoelbl-Kovacic A, Purton LE, Grebien F, Wieser R.
Cell Death and Disease; December 2019, 10(12):944, available at https://pubmed.ncbi.nlm.nih.gov/31822659/
A kinase-independent role for CDK8 in BCR-ABL1+ leukemia
Menzl I, Zhang T, Berger-Becvar A, Grausenburger R, Heller G, Prchal-Murphy M, Edlinger L, Knab VM, Uras IZ, Grundschober E, Bauer K, Roth M, Skucha A, Liu Y, Hatcher JM, Liang Y, Kwiatkowski NP, Fux D, Hoelbl-Kovacic A, Kubicek S, Melo JV, Valent P, Weichhart T, Grebien F, Zuber J, Gray NS, Sexl V.
Nature Communications; October 2019, 10(1):4741. available at https://pubmed.ncbi.nlm.nih.gov/31628323/
CEBPA-Mutated Leukemia Is Sensitive to Genetic and Pharmacological Targeting of the MLL1 Complex
Schmidt L, Heyes E, Scheiblecker L, Eder T, Volpe G, Frampton J, Nerlov C, Valent P, Grembecka J, Grebien F.
Leukemia; July 2019, 33(7): 1608–19, available at http://www.ncbi.nlm.nih.gov/pubmed/30679799
STAT3β Is a Tumor Suppressor in Acute Myeloid Leukemia
Aigner P, Mizutani T, Horvath J, Eder T, Heber S, Lind K, Just V, Moll HP, Yeroslaviz A, Fischer MJM, Kenner L, Győrffy B, Sill H, Grebien F, Moriggl R, Casanova E, Stoiber D.
Blood Advances; July 2019, 3(13): 1989–2002, available at https://www.ncbi.nlm.nih.gov/pubmed/31270081
High Activation of STAT5A Drives Peripheral T-Cell Lymphoma and Leukemia
Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer A-I, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, Prochazkova J, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A, Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L, Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R
Haematologica; May 2019, available at http://www.ncbi.nlm.nih.gov/pubmed/31123029
The Phosphatase UBASH3B/Sts-1 Is a Negative Regulator of Bcr-Abl Kinase Activity and Leukemogenesis
Mian AA, Baumann I, Liebermann M, Grebien F, Superti-Furga G, Ruthardt M, Ottmann OG, Hantschel O
Leukemia; April 2019, available at http://www.ncbi.nlm.nih.gov/pubmed/30962580
Dependence on Myb Expression Is Attenuated in Myeloid Leukaemia with N-Terminal CEBPA Mutations
Volpe G, Cauchy P, Walton DS, Ward C, Blakemore D, Bayley R, Clarke ML, Schmidt L, Nerlov C, Garcia P, Dumon S, Grebien F, Frampton J
Life Science Alliance; April 2019, 2(2): e201800207, available at https://www.ncbi.nlm.nih.gov/pubmed/30877232
Dependency on the TYK2/STAT1/MCL1 Axis in Anaplastic Large Cell Lymphoma
Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, Look AT, Turner SD, Kenner L, Merkel O
Leukemia; March 2019, 33(3): 696–709, available at http://www.ncbi.nlm.nih.gov/pubmed/30131584
Altered Splicing and Cytoplasmic Levels of TRNA Synthetases in SF3B1-Mutant Myelodysplastic Syndromes as a Therapeutic Vulnerability
Liberante FG, Lappin K, Barros EM, Vohhodina J, Grebien F, Savage KI, Mills KI
Scientific reports; February 2019, 9(1): 2678, available at http://www.ncbi.nlm.nih.gov/pubmed/30804405
Roles of Setd2 in Leukemia—Transcription, Dna-Damage, and Beyond
Skucha A, Ebner J, Grebien F
International Journal of Molecular Sciences; February 2019, 20(5), available at http://www.ncbi.nlm.nih.gov/pubmed/30818762
2018
SETD2 in MLL-Rearranged Leukemia – a Complex Case
Skucha A, Ebner J, Grebien F
Molecular & cellular oncology; August 2018, 5(4): e1503492, available at http://www.ncbi.nlm.nih.gov/pubmed/30250934
Oxytocin-like Signaling in Ants Influences Metabolic Gene Expression and Locomotor Activity
Liutkevičiutė Z, Gil-Mansilla E, Eder T, Casillas-Pérez B, Di Giglio MG, Muratspahić E, Grebien F, Rattei T, Muttenthaler M, Cremer S, Gruber CW
FASEB Journal; June 2018, 32(12): 6808–21, available at http://www.ncbi.nlm.nih.gov/pubmed/29939785
MLL-Fusion-Driven Leukemia Requires SETD2 to Safeguard Genomic Integrity
Skucha A, Ebner J, Schmöllerl J, Roth M, Eder T, César-Razquin A, Stukalov A, Vittori S, Muhar M, Lu B, Aichinger M, Jude J, Müller AC, Győrffy B, Vakoc CR, Valent P, Bennett KL, Zuber J, Superti-Furga G, Grebien F
Nature communications; May 2018, 9(1): 1983, available at http://www.ncbi.nlm.nih.gov/pubmed/29777171
Pharmacologic Inhibition of STAT5 in Acute Myeloid Leukemia
Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, Orlova A, Freund P, Ruge F, Park J, Tin G, Ahmar S, Lardeau C-H, Sadovnik I, Bajusz D, Keserű GM, Grebien F, Kubicek S, Valent P, Gunning PT, Moriggl R
Leukemia; May 2018, 32(5): 1135–46, available at http://www.ncbi.nlm.nih.gov/pubmed/29472718
STAT5BN642H Is a Driver Mutation for T Cell Neoplasia
Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, Nivarthi H, Boersma A, Kolbe T, Elabd M, Halbritter F, Pencik J, Kazemi Z, Grebien F, Hengstschläger M, Kenner L, Kubicek S, Farlik M, Bock C, Valent P, Müller M, Rülicke T, Sexl V, Moriggl R
The Journal of clinical investigation; January 2018, 128(1): 387–401, available at http://www.ncbi.nlm.nih.gov/pubmed/29200404
2017
Nilotinib-Induced Vasculopathy: Identification of Vascular Endothelial Cells as a Primary Target Site
Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, Sperr WR, Rix U, Sadovnik I, Jilma B, Schernthaner GH, Wojta J, Wolf D, Superti-Furga G, Kirchmair R, Valent P
Leukemia; November 2017, 31(11): 2388–97, available at http://www.ncbi.nlm.nih.gov/pubmed/28757617
Analysis of the Interplay between All-Trans Retinoic Acid and Histone Deacetylase Inhibitors in Leukemic Cells
Noack K, Mahendrarajah N, Hennig D, Schmidt L, Grebien F, Hildebrand D, Christmann M, Kaina B, Sellmer A, Mahboobi S, Kubatzky K, Heinzel T, Krämer OH
Archives of toxicology; May 2017, 91(5): 2191–2208, available at http://www.ncbi.nlm.nih.gov/pubmed/27807597
2016
NVT: A Fast and Simple Tool for the Assessment of RNA-Seq Normalization Strategies
Eder T, Grebien F, Rattei T
Bioinformatics (Oxford, England); December 2016, 32(23): 3682–84, available at http://www.ncbi.nlm.nih.gov/pubmed/27515738
JAK-STAT Signaling in Cancer: From Cytokines to Non-Coding Genome
Pencik J, Pham HTT, Schmoellerl J, Javaheri T, Schlederer M, Culig Z, Merkel O, Moriggl R, Grebien F, Kenner L
Cytokine; November 2016, 87: 26–36, available at http://www.ncbi.nlm.nih.gov/pubmed/27349799
Increased Survival and Cell Cycle Progression Pathways Are Required for EWS/FLI1-Induced Malignant Transformation
Javaheri T, Kazemi Z, Pencik J, Pham HT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DN, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R
Cell death & disease; October 2016, 7(10): e2419, available at http://www.ncbi.nlm.nih.gov/pubmed/27735950
2015
Pharmacological Targeting of the Wdr5-MLL Interaction in C/EBPα N-Terminal Leukemia
Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barsyte-Lovejoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senisterra G, Stukalov A, Huber KVM, Schönegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, Al-Awar R, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G
Nature chemical biology; August 2015, 11(8): 571–78, available at http://www.ncbi.nlm.nih.gov/pubmed/26167872
STAT3 Regulated ARF Expression Suppresses Prostate Cancer Metastasis
Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L
Nature communications; July 2015, 6: 7736, available at http://www.ncbi.nlm.nih.gov/pubmed/26198641
2014 and earlier
Acceleration of Bcr-Abl+ Leukemia Induced by Deletion of JAK2
Grundschober E, Hoelbl-Kovacic A, Bhagwat N, Kovacic B, Scheicher R, Eckelhart E, Kollmann K, Keller M, Grebien F, Wagner KU, Levine RL, Sexl V
Leukemia; September 2014, 28(9): 1918–22, available at http://www.ncbi.nlm.nih.gov/pubmed/24791858
Perturbation of the Mutated EGFR Interactome Identifies Vulnerabilities and Resistance Mechanisms
Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, Schell M, Grebien F, Winter G, Rix U, Eschrich S, Colinge J, Koomen J, Superti-Furga G, Haura EB
Molecular Systems Biology; November 2013, 9: 705, available at http://www.ncbi.nlm.nih.gov/pubmed/24189400
Affinity Purification Strategies for Proteomic Analysis of Transcription Factor Complexes
Giambruno R, Grebien F, Stukalov A, Knoll C, Planyavsky M, Rudashevskaya EL, Colinge J, Superti-Furga G, Bennett KL
Journal of proteome research; September 2013, 12(9): 4018–27, available at http://www.ncbi.nlm.nih.gov/pubmed/23937658
Systems-Pharmacology Dissection of a Drug Synergy in Imatinib-Resistant CML
Winter GE, Rix U, Carlson SM, Gleixner K V, Grebien F, Gridling M, Müller AC, Breitwieser FP, Bilban M, Colinge J, Valent P, Bennett KL, White FM, Superti-Furga G
Nature chemical biology; November 2012, 8(11): 905–12, available at http://www.ncbi.nlm.nih.gov/pubmed/23023260
The Growing Arsenal of ATP-Competitive and Allosteric Inhibitors of BCR-ABL
Hantschel O, Grebien F, Superti-Furga G
Cancer research; October 2012, 72(19): 4890–95, available at http://www.ncbi.nlm.nih.gov/pubmed/23002203
Optimisation of Downscaled Tandem Affinity Purifications to Identify Core Protein Complexes
Haura EB, Sacco R, Li J, Müller AC, Grebien F, Superti-Furga G, Bennett KL
Journal of integrated OMICS; May 2012, 2(1): 55–68, available at http://www.ncbi.nlm.nih.gov/pubmed/24077984
BCR-ABL Uncouples Canonical JAK2-STAT5 Signaling in Chronic Myeloid Leukemia
Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner K-U, Superti-Furga G, Sexl V
Nature chemical biology; January 2012, 8(3): 285–93, available at http://www.ncbi.nlm.nih.gov/pubmed/22286129
Targeting Allosteric Regulatory Modules in Oncoproteins: “Drugging the Undruggable”
Hantschel O, Grebien F, Superti-Furga G
Oncotarget; November 2011, 2(11): 828–29, available at http://www.ncbi.nlm.nih.gov/pubmed/22084171
Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD, Cerny-Reiterer S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G
Cell; October 2011, 147(2): 306–19, available at http://www.ncbi.nlm.nih.gov/pubmed/22000011
Using ITRAQ Combined with Tandem Affinity Purification to Enhance Low-Abundance Proteins Associated with Somatically Mutated EGFR Core Complexes in Lung Cancer
Haura EB, Müller A, Breitwieser FP, Li J, Grebien F, Colinge J, Bennett KL
Journal of proteome research; January 2011, 10(1): 182–90, available at http://www.ncbi.nlm.nih.gov/pubmed/20945942
CD14 Is a Coreceptor of Toll-like Receptors 7 and 9
Baumann CL, Aspalter IM, Sharif O, Pichlmair A, Blüml S, Grebien F, Bruckner M, Pasierbek P, Aumayr K, Planyavsky M, Bennett KL, Colinge J, Knapp S, Superti-Furga G
The Journal of experimental medicine; November 2010, 207(12): 2689–2701, available at http://www.ncbi.nlm.nih.gov/pubmed/21078886
A Potent and Highly Specific FN3 Monobody Inhibitor of the Abl SH2 Domain
Wojcik J, Hantschel O, Grebien F, Kaupe I, Bennett KL, Barkinge J, Jones RB, Koide A, Superti-Furga G, Koide S
Nature structural & molecular biology; April 2010, 17(4): 519–27, available at http://www.ncbi.nlm.nih.gov/pubmed/20357770
Stat5 Is Indispensable for the Maintenance of Bcr/Abl-Positive Leukaemia
Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, Hennighausen L, Poli V, Beug H, Moriggl R, Sexl V
EMBO molecular medicine; March 2010, 2(3): 98–110, available at http://www.ncbi.nlm.nih.gov/pubmed/20201032
Stat5 Regulates Cellular Iron Uptake of Erythroid Cells via IRP-2 and TfR-1
Kerenyi MA, Grebien F, Gehart H, Schifrer M, Artaker M, Kovacic B, Beug H, Moriggl R, Müllner EW
Blood; November 2008, 112(9): 3878–88, available at http://www.ncbi.nlm.nih.gov/pubmed/18694996
Structural Coupling of SH2-Kinase Domains Links Fes and Abl Substrate Recognition and Kinase Activation
Filippakopoulos P, Kofler M, Hantschel O, Gish GD, Grebien F, Salah E, Neudecker P, Kay LE, Turk BE, Superti-Furga G, Pawson T, Knapp S
Cell; September 2008, 134(5): 793–803, available at http://www.ncbi.nlm.nih.gov/pubmed/18775312
Stat5 Activation Enables Erythropoiesis in the Absence of EpoR and Jak2
Grebien F, Kerenyi MA, Kovacic B, Kolbe T, Becker V, Dolznig H, Pfeffer K, Klingmüller U, Müller M, Beug H, Müllner EW, Moriggl R
Blood; May 2008, 111(9): 4511–22, available at http://www.ncbi.nlm.nih.gov/pubmed/18239084
The Different Functions of Stat5 and Chromatin Alteration through Stat5 Proteins
Kornfeld JW, Grebien F, Kerenyi MA, Friedbichler K, Kovacic B, Zankl B, Hoelbl A, Nivarti H, Beug H, Sexl V, Muller M, Kenner L, Mullner EW, Gouilleux F, Moriggl R
Frontiers in Bioscience; May 2008, (13): 6237–54, available at http://www.ncbi.nlm.nih.gov/pubmed/18508657
Erythroid Progenitor Renewal versus Differentiation: Genetic Evidence for Cell Autonomous, Essential Functions of EpoR, Stat5 and the GR
Dolznig H, Grebien F, Deiner EM, Stangl K, Kolbus A, Habermann B, Kerenyi MA, Kieslinger M, Moriggl R, Beug H, Müllner EW
Oncogene; May 2006, 25(20): 2890–2900, available at http://www.ncbi.nlm.nih.gov/pubmed/16407844
Cell Size Control: New Evidence for a General Mechanism
Grebien F, Dolznig H, Beug H, Mullner EW
Cell cycle (Georgetown, Tex.); March 2005, 4(3): 418–21, available at http://www.ncbi.nlm.nih.gov/pubmed/15703475
Evidence for a Size-Sensing Mechanism in Animal Cells
Dolznig Helmut, Grebien F, Sauer T, Beug H, Müllner EW
Nature cell biology; September 2004, 6(9): 899–905, available at http://www.ncbi.nlm.nih.gov/pubmed/15322555
The Grebien Group 